SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-157266"
 

Search: onr:"swepub:oai:DiVA.org:liu-157266" > Vedolizumab in Refr...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Riviere, PaulineKatholieke Univ Leuven, Belgium (author)

Vedolizumab in Refractory Microscopic Colitis : An International Case Series

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2018-10-17
  • Oxford University Press,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-157266
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-157266URI
  • https://doi.org/10.1093/ecco-jcc/jjy169DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background Evidence for second-line therapy in patients with microscopic colitis [MC] failing budesonide is scarce, although anti-tumour necrosis factors [anti-TNFs], methotrexate and azathioprine have been reported to be effective in small cohort studies. Vedolizumab, a monoclonal antibody targeting 47-integrin, prevents homing of T-cells to the gut. We evaluated clinical remission with vedolizumab in budesonide-refractory MC patients. Methods We solicited gastroenterologists in Europe and Canada for cases of MC treated with vedolizumab. Vedolizumab 300 mg IV was administered at weeks 0, 2 and 6, and then every 8 weeks. Clinical remission and histological remission were defined as less than three stools per day and normalization of histology, respectively, after induction treatment. Results Eleven cases were retrieved (nine females, lymphocytic colitis [LC] n = 5, collagenous colitis [CC] n = 6). Median [interquartile range] disease duration at vedolizumab initiation was 51 [29-70] months. Nine of 11 patients had failed one immunosuppressant and ten of 11 at least one anti-TNF agent. After three infusions of vedolizumab, clinical remission was observed in 5/11 patients [two LC and three CC] of whom three remained well with maintenance therapy [median duration of 13 months]. Biopsies were obtained from 9/11 patients. Histological remission was observed in 3/4 patients with clinical remission [2/3 CC, 1/1 LC] and 0/5 patients without clinical improvement. Conclusion In a series of highly refractory MC patients, vedolizumab induced clinical remission in 5/11 subjects, of whom 75% showed normalized histology. Larger randomized trials are needed to assess the efficacy of vedolizumab in patients with MC.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Münch, Andreas,1970-Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Magtarmmedicinska kliniken(Swepub:liu)andsa76 (author)
  • Michetti, PierreGastroenterol La Source Beaulieu, Switzerland (author)
  • Chande, NileshWestern Univ, Canada (author)
  • de Hertogh, GertKatholieke Univ Leuven, Belgium (author)
  • Schoeters, PatrickAZA Herentals, Belgium (author)
  • Ferrante, MarcKatholieke Univ Leuven, Belgium (author)
  • Vermeire, SeverineKatholieke Univ Leuven, Belgium (author)
  • Van Assche, GertKatholieke Univ Leuven, Belgium (author)
  • Katholieke Univ Leuven, BelgiumAvdelningen för neuro- och inflammationsvetenskap (creator_code:org_t)

Related titles

  • In:Journal of Crohn's & Colitis: Oxford University Press13:3, s. 337-3401873-99461876-4479

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view